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Introduction: Edoxaban is an oral, direct, once-daily factor Xa inhibitor. This study evaluated the safety and efﬁ-
cacy of edoxaban compared to subcutaneous enoxaparin in Japanese patients undergoing hip fracture surgery.
Materials and methods: In this multicenter, randomized, open-label, active-comparator, phase 3 trial, 92 patients
were randomized 2:1 to receive edoxaban 30 mg once daily (n = 62) or enoxaparin sodium (enoxaparin)
2000 IU (equivalent to 20mg) twice daily (n= 30) for 11 to 14 days. The primary endpoints were the incidence
of major or clinically relevant non-major (CRNM) bleeding and incidence of any bleeding events (major, CRNM,
or minor bleeding). Secondary efﬁcacy endpoints included the incidence of thromboembolic events, venous
thromboembolism-related deaths, and all-cause deaths. Additional adverse events were recorded throughout
the study.
Results: In the edoxaban and enoxaparin treatment groups, the incidence of major or CRNM bleeding was 3.4%
and 6.9%, respectively, while any bleeding event occurred in 25.4% and 17.2% of patients, respectively. The inci-
dence of thromboembolic events was 6.5% in the edoxaban group and 3.7% in the enoxaparin group. All events
were asymptomatic deep vein thrombosis. The incidence of adverse events was 72.9% and 82.8% in the edoxaban
and enoxaparin groups, respectively.
Conclusions: Compared to subcutaneous enoxaparin 2000 IU twice daily, oral edoxaban 30mgonce daily demon-
strated similar safety and efﬁcacy in the prevention of thromboembolic events in Japanese patients undergoing
hip fracture surgery.
Clinical trials registration number: NCT01181141.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).rse events; ALT, alanine amino-
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Patients undergoing lower-limb orthopedic surgeries (LLOS) are
at an increased risk for developing deep vein thrombosis (DVT) and
pulmonary embolism (PE) if they are not provided with timely and ad-
equate thromboprophylaxis [1,2]. The incidence of postoperative DVT is
relatively high among patients who do not receive thromboprophylaxis
undergoing total knee arthroplasty (TKA; 41%–85%), total hip
arthroplasty (THA; 42%–57%), and hip fracture surgery (HFS; 46%–
60%) [3]. PE, which in most cases is caused by DVT, can be fatal and is
associatedwith a 14% in-hospital mortality rate; in serious cases accom-
panied by shock, themortality rate is approximately 30% [4]. It has been
reported that approximately 40% of patients who die of a PE do sowith-
in 1 hour of onset [5]. PE has been recognized as a signiﬁcantthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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guidelines from the Japanese Circulation Society and the American Col-
lege of Chest Physicians underscore the importance of preventing post-
operative thrombosis and strongly recommend the use of adequate
anticoagulant therapy soon after surgery [1,2].
Traditional anticoagulants (like heparin and warfarin) have limited
use for venous thromboembolism (VTE) prevention in Japan because
little is known about their efﬁcacy in postoperative DVT prevention,
adverse drug reactions (ADRs), and bleeding risks in this patient
population. Enoxaparin, a low-molecular weight heparin (LMWH),
and fondaparinux, an indirect factor Xa inhibitor, are efﬁcacious in
preventing VTE in patients undergoing LLOS, compared to placebo
[6,7], and have both been approved in Japan for thromboprophylaxis
in patients undergoing lower-limb orthopedic surgery [2]. Both drugs
require subcutaneous injections (sc) administered once or twice daily,
which may hinder patient adherence to therapy [8,9].
Edoxaban is an oral, once-daily, selective, direct factor Xa inhibitor
that demonstrates a linear pharmacokinetic (PK) proﬁle, a rapid onset
of action with approximately 62% oral bioavailability [10], and low
intra-subject variability [11]. Previous phase 2 studies in patients under-
going TKA [12] and THA [13,14] have demonstrated that edoxaban is
associatedwith dose-dependent reductions in VTEwith a low incidence
of bleeding events that do not signiﬁcantly increase with dose. In addi-
tion, edoxaban demonstrated efﬁcacy and safety proﬁles similar to sc
enoxaparin sodium for the prevention of thromboembolic events in
patients undergoing THA [13]. The objective of this phase 3 study was
to investigate the safety and efﬁcacy of edoxaban in Japanese patients
undergoing HFS.
Materials and Methods
Study Design
This was a multicenter, open-label, active-comparator, phase 3 trial
(ClinicalTrials.gov Identiﬁer: NCT01181141). Japanese patients were
randomized 2:1 to receive an oral dose of edoxaban 30 mg once daily
or the active control, enoxaparin 2000 IU sc every 12 hours (BID),
which is the approved dosing regimen in Japan [15]. Edoxaban was ini-
tiated within 6 to 24 hours after surgery; enoxaparin was initiated
within 24 to 36 hours after surgery (the standard of care in Japan).
Both treatments were continued for 11 to 14 days. Concomitant use of
mechanical physiotherapy (intermittent pneumatic compression or
elastic stockings) was permitted.
Venography of both lower limbs was performed within 24 hours
after the end of study treatment or treatment discontinuation; however,
if it could not be performedwithin 24 hours for reasons such as difﬁcul-
ty establishing an intravenous line, it was performed within 96 hours.
If DVT was suspected during the study, it was visually conﬁrmed with
diagnostic imaging. Similarly, suspected PE was conﬁrmed by pulmo-
nary scintigraphy or arteriography, computed tomography (CT) scan,
or other appropriate imaging techniques. Study treatmentwas immedi-
ately discontinued if a suspected DVT or PE was conﬁrmed and appro-
priate interventions were taken.
Investigations, observations, examinations, and urine and blood sam-
ple collections (for urinalysis, edoxaban plasma concentration measure-
ments, pharmacodynamic [PD] indices assessments, and hematology
tests) were performed during the presurgical evaluation, pretreatment
(postsurgery), on day 7, and on the completion day of treatment.
Follow-up examinations were performed 25 to 35 days after the last
dose of the study drug. The occurrence of thromboembolic events, bleed-
ing, and all other adverse events (AEs) were recorded throughout the
study and the follow-up period. If applicable, site, duration, and total
time of physiotherapy use were recorded throughout the course of the
study. The studywas conducted in compliancewith the ethical principles
in the Declaration of Helsinki, the Pharmaceutical Affairs Law Articles
14–3 and 80–2, and the Ministry of Health and Welfare Ordinanceon Good Clinical Practice (GCP). All study protocols, information for pa-
tients, and informed consent forms received approval from an indepen-
dent review board.
Patient Selection
Men and women of at least 20 years of age who provided written
informed consent and were scheduled to undergo surgery within
10 days for inner or outer femoral neck (trochanteric or subtrochanteric)
fracture were eligible for enrollment. Prior to surgery, patients were con-
sidered ineligible if theywere at increased risk for bleeding (e.g., a history
of intracranial bleeding or recent gastrointestinal [GI] bleeding) or in-
creased risk for VTE (i.e., had a prior VTE, history of fracture or prosthetic
replacement of lower limbs within 6 months, or recent occurrence of
myocardial infarction, cerebral infarction, or transient ischemic attack).
Additional reasons for exclusion included body weight of b40 kg,
current use of antithrombotic therapy for another indication, severe
renal impairment (creatinine clearance b30 mL/min) or evidence of he-
patic impairment, conditions preventing bilateral venography, pregnancy
or lactation, and any contraindications to enoxaparin. After surgery, pa-
tients could also be excluded if they experienced any abnormal bleeding
at the site of spinal anesthesia administration, experienced abnormal or
excessive bleeding during or immediately after surgery, were unable to
take oral medications, or required additional surgery after the initial
HFS until the start of study drug administration.
Study Endpoints
The primary endpoints were the incidence of major or clinically rel-
evant non-major (CRNM) bleeding and the incidence of any bleeding
event (major, CRNM, or minor bleeding) from the start of treatment to
completion day of treatment, inclusive. Secondary safety endpoints
included the incidence of individual bleeding events, AEs, ADRs, vital
signs and laboratory test data. AEs were reported from the start of the
treatment up to the end of the follow-up period (25–35 days after
treatment).
Secondary efﬁcacy endpoints included the proportion of patients
who experienced the composite of asymptomatic DVT detected by the
end-of-study venography, conﬁrmed symptomatic DVT, or conﬁrmed
symptomatic PE; the proportion of patients who experienced the com-
posite of symptomatic or proximal DVT, symptomatic PE, or VTE-related
mortality; the incidence of asymptomatic or symptomatic DVT; the inci-
dence of symptomatic or proximal DVT; the incidence of conﬁrmed,
symptomatic PE; the incidence of VTE-related mortality; and the
incidence of all-cause mortality. To ensure objectivity, independent
committees assessed bleeding events and thromboembolic events
under blinded conditions.
Major bleeding was deﬁned as fatal bleeding, clinically overt bleed-
ing accompanied by a decrease in hemoglobin of N2 g/dL, clinically
overt bleeding requiring transfusion (excluding predonated autologous
blood) with more than 4 units of blood (1 unit = approximately
200 mL), retroperitoneal bleeding, intracranial bleeding, intraocular
bleeding or intrathecal bleeding, and bleeding requiring repeat surgery.
CRNM bleeding was deﬁned as bleeding that did not fall under the
category of major bleeding but corresponded to any of the following:
hematoma of ≥5 cm in longest diameter, epistaxis or gingival bleeding
that occurred in the absence of external factors and lasts≥5 minutes, GI
bleeding, gross hematuria that is persistent after 24 hours of onset, and
other bleeding thatwas assessed to be clinically signiﬁcant by the inves-
tigator or sub-investigator. Any bleeding event that did not meet major
or CRNM criteria was categorized as a minor bleeding event.
In addition to safety and efﬁcacy outcomes, PD indices (prothrombin
time [PT], prothrombin time expressed as international normalized
ratio [PT-INR], and activated partial thromboplastin time [aPTT]), and
edoxaban plasma concentrations were measured at various time points
as described below.
1018 T. Fuji et al. / Thrombosis Research 133 (2014) 1016–1022Blood Sampling for Pharmacodynamic and Edoxaban Plasma Concentra-
tion Measures
Blood sampling formeasurement of edoxaban plasma concentrations
was performed on day 7 of study treatment (predose and 1–3 hours
postdose), at the completion of study treatment (predose), or at discon-
tinuation. The concentration was measured by liquid chromatography
tandem mass spectrometry (Quotient Bioresearch [Rushden] Ltd.;
Northamptonshire, United Kingdom). The lower limit of quantiﬁcation
was 1 ng/ml.
Blood sampling formeasurement of PD indiceswas performed at the
following time points: presurgical examination, pretreatment, day 7 of
study treatment (predose and 1–3 hours postdose), predose on com-
pletion day of study treatment, and at the time of discontinuation.
While presurgical PDmeasurementsweremade at the study sites,mea-
surements during the treatmentwere performed at a central laboratory
(SRL, Inc; Tokyo, Japan) and were not to be made at the investigation
site to avoid effects on assessment (unless they were for treatment of
an AE or an emergency occurred).
Statistical Analysis
The full analysis set was deﬁned as all patients enrolled in the study
who received at least 1 dose of study drug and had no signiﬁcant GCP
violations. Patients who did not develop symptomatic DVT or PE, but
in whom venography was not appropriately performed, were excluded
from this group. The per-protocol set was deﬁned as patients in the full
analysis set, but excluded those with who had any violations of the
inclusion and exclusion criteria, who took prohibited concomitant
medications or therapies, or who had a study treatment compliance
rate of b80%. The safety analysis set included all patients who received
at least 1 dose of study drug, had safety data, and had no signiﬁcant
GCP violations. The PD and PK analysis sets comprised those patientsPatients 
randomized
(N=92)
Randomized to 
edoxaban 30 mg 
(n = 62)
Patients treated with at 
least one dose (safety 
analysis set)
(n = 59)
Did not receive study 
drug
(n = 3)
Excluded from the full 
analysis set:
Venography not 
assessable
(n = 16)
Full analysis set
(n = 46) Excluded from the per-
protocol seta (n = 4) 
Reasons for exclusion:
• Violation of 
exclusion criteria (n 
= 2)
• Poor treatment 
compliance (n = 8)
• Violation 
concomitant 
medications (n = 3)
Per-protocol set
(n = 42)
Fig. 1. Patient disposition. aMultiple answers were allowed; patients within the per-protocol set with at least 1 set of valid PD index or plasma
drug concentration data, respectively.
Baseline demographics and characteristics are reported here for the
safety analysis set andwere reported by summary statistics according to
treatment group. Between-treatment comparisons were made using
the χ2 test or Fisher’s exact test for categorical data, the Wilcoxon
rank-sum test for ordinal data, and the 2-sample t-test for continuous
data.
Primary analyses of the primary and secondary safety endpoints
were performed for the safety analysis set. Primary analyses of the efﬁ-
cacy endpoints were performed for the full analysis set. Incidence of
major or CRNM bleeding or any bleeding (primary safety endpoints)
95% conﬁdence intervals (CIs) were calculated by treatment group, as
well as the differences between treatment groups and the correspond-
ing 95% CIs. For the secondary endpoints of individual bleeding events,
AEs, ADRs, and thromboembolic events, incidences and 95% CIs were
calculated by treatment group. In addition, for the incidence of individ-
ual bleeding events and thromboembolic events, the differences be-
tween treatment groups and corresponding 95% CIs were determined.
Laboratory data, vital signs, and other observations were reported
using summary statistics calculated by treatment group.
PD indiceswere reported for the corresponding PD analysis set using
summary statistics for measured values. Changes from pretreatment
were calculated for each parameter by treatment group at each time
point. Similarly, summary statistics of edoxaban plasma concentrations
were calculated for the PK analysis set.
The sample size (N=90) for this analysis was determined to ensure
that a major or CRNM bleeding event would occur in at least 1 patient
with an 80% or higher probability in any situation for the edoxaban
(n ≥ 41) and enoxaparin (n ≥ 28) groups. This determination was
based on the assumption that these bleeding events would occur at a
similar rate, as has been previously reported for edoxaban and
enoxaparin. However, the target number of patients was set at 60Randomized to 
enoxaparin 2000 IU
(n = 30)
Patients treated with at 
least one dose (safety 
analysis set)
(n = 29)
Did not receive study 
drug
(n = 1)
Excluded from the full 
analysis set:
Venography not 
assessable
(n = 3)
Full analysis set
(n = 27)
Per-protocol set
(n = 26)
Excluded from the per-
protocol seta (n = 1) 
Reasons for exclusion:
• Violation of 
exclusion criteria (n 
= 0)
• Poor treatment 
compliance (n = 2)
• Violation 
concomitant 
medications (n = 2)
multiple reasons for exclusion were counted once for each reason.
Table 1
Baseline demographics and characteristics.a
Characteristic Edoxaban (N = 59) Enoxaparin (N = 29)
Sex
Men 11 (18.6) 7 (24.1)
Women 48 (81.4) 22 (75.9)
Age, y (mean ± SD) 76.5 ± 11.0 75.6 ± 12.0
b75 20 (33.9) 12 (41.4)
≥75 39 (66.1) 17 (58.6)
Weight, kg (mean ± SD) 52.3 ± 8.4 55.1 ± 10.0
b50 21 (35.6) 10 (34.5)
≥50 38 (64.4) 19 (65.5)
Site of surgery
Medial femoral neck 30 (50.8) 10 (34.5)
Lateral femoral neck (trochanteric section) 26 (44.1) 18 (62.1)
Lateral femoral neck (subtrochanteric section) 3 (5.1) 1 (3.4)
Method of surgery
Femoral head replacement 21 (35.6) 6 (20.7)
Prosthetic joint replacement 0 (0.0) 0 (0.0)
Osteosynthesis 38 (64.4) 23 (79.3)
Duration from the end of surgery to the start of study treatment, h:min (mean ± SD) 20:01 ± 2:47 27:02 ± 2:56
≥6 to b12 0 (0.0) -
≥12 to b18 18 (30.5) -
≥18 to ≤24 41 (69.5) -
≥24 to b30 - 24 (82.8)
≥30 to b36 - 5 (17.2)
Creatinine clearance, mL/min (mean ± SD) 63.7 ± 22.4 73.2 ± 30.8
b50 24 (40.7) 8 (27.6)
≥50 to b80 23 (39.0) 10 (34.5)
≥80 12 (20.3) 11 (37.9)
Use of physiotherapy
Intermittent pneumatic compression
Foot sole 16 (27.1) 8 (27.6)
Lower legs and thigh 13 (22.0) 7 (24.1)
Elastic stockings 47 (79.7) 20 (69.0)
Concomitant NSAID use 59 (100.0) 29 (100.0)
Data provided as n (%) unless indicated otherwise. SD = standard deviation; NSAID = non-steroidal anti-inﬂammatory drug.
a Safety analysis set.
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could be randomly assigned to a 2:1 ratio (edoxaban:enoxaparin).
Results
Patients
Between October 2008 and August 2009, 92 patients were random-
ized and 76 completed the study. Among the 16 patients who did not
complete the study, 12 were in the edoxaban treatment group and 4
received enoxaparin. One patient each discontinued due to a DVT or
PE, major bleeding, an AE, or were lost to follow-up, 2 patients were
discontinued at the investigators discretion, and 3 patients each volun-
tarily withdrew or became ineligible for continued participation during
the course of the study. In the enoxaparin group, reasons for discontin-
uation were an AE, voluntary withdrawal, ineligibility, or lost to follow
up, 1 patient each. Four patients did not receive study drug and 19
were not assessable by venography, leaving 88 and 73 patients in the
safety and full analysis sets, respectively. An additional 5 patientsTable 2
Incidence of bleeding events during the treatment period.a
Bleeding Event Edoxaban (N = 59)
nb % (95% CI)
Major or CRNM bleeding 2 3.4 (0.9 to 11.5)
Any bleeding 15 25.4 (16.1 to 37.8)
Major bleeding 1 1.7(0.3 to 9.0)
CRNM bleeding 1 1.7 (0.3 to 9.0)
Minor bleeding 13 22.0 (13.4 to 34.1)
CI = conﬁdence interval; CRNM = clinically relevant non-major.
a Safety analysis set.
b Number of subjects with events.were excluded from the per-protocol set due to various protocol viola-
tions (Fig. 1). No additional patients were excluded from the PK or PD
analysis sets (edoxaban only, n = 42). Baseline characteristics were
similar between the treatment groups, although creatinine clearance
was lower in the edoxaban group (63.7 ± 22.4 mL/min) than in the
enoxaparin group (73.2 ± 30.8 mL/min); however, this difference was
not statistically signiﬁcant (Table 1). Overall, the majority of patients
were female (79.5%) and ≥75 years of age (63.6%). Approximately
one-third of patients had a body weight b50 kg (35.2%) and creatinine
clearance b50 mL/min (36.4%). The mean duration of treatment with
edoxaban or enoxaparin was 12.1 and 12.2 days, respectively.
Primary Safety Endpoints
The incidence of major or CRNM bleeding was observed in 3.4%
(2/59; 95% CI 0.9–11.5) of patients in the edoxaban group and 6.9%
(2/29; 95% CI 1.9–22.0) in the enoxaparin group (Table 2). The absolute
difference (deﬁned as the difference in the incidence of bleeding events
between the edoxaban group and the enoxaparin group, the sameEnoxaparin (N = 29) Absolute Difference
nb % (95% CI) % (95% CI)
2 6.9 (1.9 to 22.0) −3.5 (−18.8 to 6.0)
5 17.2 (7.6 to 34.5) 8.2 (−11.5 to 23.9)
1 3.4 (0.6 to 17.2) −1.8 (−15.6 to 6.1)
1 3.4 (0.6 to 17.2) −1.8 (−15.6 to 6.1)
3 10.3 (3.6 to 26.4) 11.7 (−6.5 to 25.5)
Table 3
Incidence of adverse events, serious adverse events, and drug reactions, from the start of
treatment to the end of follow-up period.a
Treatment Group Edoxaban (N = 59) Enoxaparin (N = 29)
Adverse events
n 43 24
% (95% CI) 72.9 (60.4 to 82.6) 82.8 (65.5 to 92.4)
Serious adverse events
n 3 3
% (95% CI) 5.1 (1.7 to 13.9) 10.3 (3.6 to 26.4)
Adverse drug reactions
n 22 11
% (95% CI) 37.3 (26.1 to 50.0) 37.9 (22.7 to 56.0)
Adverse events reported by ≥10% of patients in either treatment group, n (%)b
Urinary tract infections 7 (11.9) 4 (13.8)
Diarrhea 3 (5.1) 3 (10.3)
Decubitus ulcer 0 3 (10.3)
Alanine aminotransferase increased 0 4 (13.8)
Aspartate aminotransferase increased 2 (3.4) 5 (17.2)
γ-Glutamyltransferase increased 2 (3.4) 3 (10.3)
Blood urine present 9 (15.3) 4 (13.8)
CI = conﬁdence interval; breported by MedDRA preferred term.
a Safety analysis set.
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bleeding event (major, CRNM, and minor bleeding) was 25.4% (15/59;
95% CI 16.1–37.8) and 17.2% (5/29; 95% CI 7.6–34.5) in the edoxaban
and the enoxaparin groups, respectively. The absolute difference was
8.2% (95% CI−11.5–23.9).Secondary Safety Endpoints
Individual Bleeding Events
The incidence of major bleedingwas 1.7% (1/59; 95% CI 0.3–9.0) and
3.4% (1/29; CI 0.6–17.2) in the edoxaban and enoxaparin groups,
respectively. The absolute difference was−1.8% (95% CI,−15.6–6.1;
Table 2). The major bleeding events included GI hemorrhage in the
edoxaban group and postprocedural hematoma in the enoxaparin
group. Both events were classiﬁed as clinically overt bleeding accompa-
nied by a decrease in hemoglobin of N2 g/dL. The percentage of patients
who had a CRNM bleeding event was 1.7% (1/59; 95% CI 0.3–9.0; GI
hemorrhage) and 3.4% (1/29; 95% CI 0.6–17.2; postprocedural hemato-
ma of ≥5 cm in diameter) in the edoxaban and enoxaparin groups, re-
spectively. The absolute difference was −1.8% (95% CI, −15.6–6.1).
The incidence of minor bleeding was 22% (13/59; 95% CI 13.4–34.1)
and 10.3% (3/29; 95% CI 3.6–26.4) in the edoxaban and enoxaparin
groups, respectively. The absolute difference was 11.7% (95% CI−6.5–
25.5).Table 4
Incidence of venous thromboembolism during the treatment period.a
Thromboembolic Event E
n
Composite VTE (symptomatic or asymptomatic DVT, symptomatic PE) 3
Composite of symptomatic or proximal DVT, symptomatic PE, or VTE-related death 0
Any DVT 3
Asymptomatic DVT 3
Asymptomatic proximal 0
Asymptomatic distal 3
Symptomatic DVT 0
Symptomatic or proximal DVT 0
Symptomatic PE 0
VTE-related death 0
All–cause death 0
CI = conﬁdence interval; VTE = venous thromboembolism; DVT = deep vein thrombosis; PE
a Full analysis set.
b Number of subjects with events.Adverse Events
The incidence of AEs was 72.9% (43/59; 95% CI 60.4–82.6) in the
edoxaban group and 82.8% (24/29; 95% CI 65.5–92.4) in the enoxaparin
group (Table 3). The most frequently reported AEs (reported by ≥10%
of patients in either treatment group) included blood urine present,
urinary tract infections, alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) increase, diarrhea, decubitus ulcer, and
γ-glutamyltransferase increase (Table 3). Increased ALT and AST levels
were reported more frequently in the enoxaparin group compared to
the edoxaban group. Subcutaneous hemorrhage was reported for 4
(6.8%) patients in the edoxaban treatment group and 1 (3.4%) patient
in the enoxaparin treatment group. The majority (N70%) of AEs were
mild in intensity. The incidence of AEs, excluding bleeding events and
hepatic dysfunction, was 57.6% (34/59) and 69.0% (20/29) for the
edoxaban and enoxaparin treatment groups, respectively.
The incidence of ADRs was 37.3% (22/59; 95% CI 26.1–50.0) in the
edoxaban group and 37.9% (11/29; 95% CI 22.7–56.0) in the enoxaparin
group. The most common ADRs, which occurred in ≥5% of patients in
either the edoxaban or enoxaparin groups, included ALT increase
(0% and 10.3%, respectively), AST increase (0% and 13.8%, respectively),
γ-glutamyltransferase increase (3.4% and 10.3%, respectively), blood
urine present (6.8% and 3.4%, respectively), and postprocedural hema-
toma (1.7% and 6.9%, respectively).
Serious AEs (SAEs) occurred in 5.1% (3/59; 95% CI 1.7–13.9) and
10.3% (3/29; 95% CI 3.6–26.4) of the patients in the edoxaban and
enoxaparin groups, respectively. Fracture displacement occurred in 2
patients in the edoxaban group (1 event each) while it occurred twice
in 1 patient in the enoxaparin group. Other SAEs included 1 subdural
hematoma in the edoxaban group and 1 each of postoperative wound
infection and thoracic vertebral fracture (2 different patients) in the
enoxaparin group. Of the SAEs, subdural hematoma in the edoxaban
group and postoperative wound infection in the enoxaparin group
were considered treatment related. No deaths occurred during the
study. Three AEs led to treatment discontinuation: 2 patients receiving
edoxaban experienced GI bleeding and 1 patient receiving enoxaparin
experienced a postoperative wound infection.Secondary Efﬁcacy Endpoints
The efﬁcacy endpoint of composite thromboembolic events
(asymptomatic DVT detected by the end-of-study venography, con-
ﬁrmed symptomatic DVT, or conﬁrmed symptomatic PE) occurred in
6.5% (3/46; 95% CI, 2.2–17.5) of patients in the edoxaban group and
3.7% (1/27; 95% CI, 0.7–18.3) in the enoxaparin group (Table 4). All
events were asymptomatic distal DVT; there were no occurrences of
asymptomatic proximal DVT, symptomatic PE or DVT, or death in either
treatment group.doxaban (N = 46) Enoxaparin (N = 27) Absolute Difference
b % (95% CI) nb % (95% CI) % (95% CI)
6.5 (2.2 to 17.5) 1 3.7 (0.7 to 18.3) 2.8 (−12.4 to 14.2)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
6.5 (2.2 to 17.5) 1 3.7 (0.7 to 18.3) 2.8 (−12.4 to 14.2)
6.5 (2.2 to 17.5) 1 3.7 (0.7 to 18.3) 2.8 (−12.4 to 14.2)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
6.5 (2.2 to 17.5) 1 3.7 (0.7 to 18.3) 2.8 (−12.4 to 14.2)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
0.0 (0.0 to 7.7) 0 0.0 (0.0 to 12.5) 0.0 (−12.5 to 7.7)
= pulmonary embolism; NC = not calculated.
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One (1.7%) patient in the edoxaban group and 5 (17.2%) patients in
the enoxaparin group had elevated ALT levels ≥1.5 times the upper
limit of normal (ULN). Two patients in the edoxaban group and 6
patients in the enoxaparin group had elevated AST ≥1.5 times the
ULN. Elevations in ALT/AST were seen in 4 patients (13.8%) in the
enoxaparin group. No patient in the edoxaban group experienced ALT,
AST, or ALT/AST elevations ≥3 times the ULN or total bilirubin eleva-
tions ≥2 times the ULN. ALT was elevated ≥3 times the ULN in 1
(3.4%) patient in the enoxaparin group.
Pharmacokinetic and Pharmacodynamic Analyses
The mean (standard deviation) plasma edoxaban concentrations
were 24.3 (12.5) ng/mL, 129.9 (111.1) ng/mL, and 23.3 (11.1) ng/mL
at predose on day 7, 1 to 3 hours postdose on day 7, and at predose
on the completion day of treatment, respectively.
In the edoxaban group, PT, PT-INR, and aPTT were prolonged at 1 to
3 hours postdose on day 7 of treatment compared with those at pre-
treatment. No prolongation was observed in the enoxaparin group
(Fig. 2). The observed increases in PT, PT-INR, and aPTT values from
pretreatment levels were nearly linear to the observed increase in
edoxaban plasma concentrations at 1 to 3 hours postdose on day 7
(data not shown).
Discussion
In Japanese patients undergoing HFS, VTE prophylaxis with oral
edoxaban 30mg once daily led to similar rates of major or CRNMbleed-
ing events compared to sc enoxaparin 2000 IU BID, while the incidence
of any bleeding event (major bleeding, CRNMbleeding, or minor bleed-
ing) was higher in the edoxaban group (absolute difference 8.2%).
Although the incidence of major or CRNM bleeding in the edoxaban
group in this study was low (3.4%) and in line with rates reported in
phase 2b and phase 3 studies in Japanese patients undergoing TKA
[12,16] or THA [13,17,18], the incidence of any bleeding event (15/59;
25.4%)was higher than that reported for the edoxaban 30mg treatment
group in the phase 2b dose-ranging Japanese TKA study (10.7%, 11/103)
[12]. These data suggest that the difference in overall bleeding rates ob-
served in the current study may be attributed to higher rates of minor
bleeding. The increased incidence of any bleeding event, primarily
minor bleeding, may be due to the characteristics of patients undergo-
ing HFS who were enrolled in this study; they were of lower body
weight compared to the patients enrolled in the phase 2b TKA study
(52.3 vs 60.1 kg, respectively) [12] and 40.7% had a creatinine clearance
of b50 mL/min. These patient characteristics, low body weight and
decreased renal function, have been shown to increase edoxaban con-
centrations in patients with atrial ﬁbrillation [19].
Additional safety assessments showed no clear differences in the in-
cidence of AEs between the 2 treatment groups (72.9% and 82.8% in the
edoxaban and enoxaparin groups, respectively). Among the common
AEs observed in both treatment groups, none were speciﬁc to the
edoxaban group, while elevated liver function tests occurred at a higher
rate in the enoxaparin group. It should be noted that elevated serum
transaminase levels are a recognized class-effect of heparins. These ele-
vations are reversible and considered benign [20]. AEs not inclusive of
bleeding or hepatic dysfunction were reported by 57.6% and 69.0% pa-
tients in the edoxaban and enoxaparin treatment groups, respectively,
and therefore made up the majority of all AEs reported in this study.
The incidence of VTE was lower in the enoxaparin treatment group
than observed in the edoxaban treatment group. All occurrences of
VTE were asymptomatic distal DVT and the rate of VTE occurrence
was comparable between the 2 groups. The rate of VTE in the edoxaban
group in this study was low and similar to those reported in previous
phase 2b and phase 3 Japanese LLOS studies [12,13,16,17]. Theincidence of VTE in a Japanese phase 3, placebo-controlled study of
enoxaparin 2000 IU BID was 20.0% for THA patients and 29.8% for TKA
patients [6]. As such, adequate prophylaxis of thromboembolic events
was achieved in both edoxaban and enoxaparin groups in the present
study.
Prolongation of mean edoxaban PT, PT-INR, and aPTT values were
observed at 1 to 3 hours postdose on day 7 and coincide with a corre-
sponding increase in mean edoxaban concentrations. The PD results
observed in this study are very similar to those reported for the phase
2b Japanese TKA study [12].
1022 T. Fuji et al. / Thrombosis Research 133 (2014) 1016–1022Enoxaparin and fondaparinux have been evaluated in placebo-
controlled, double-blind studies in Japanese patients undergoing major
orthopedic surgery [6,7]. However, sc administration of enoxaparin and
fondaparinux may involve clinical implications that can restrict their
use in patients undergoing orthopedic surgeries. Additionally, the long-
termuse of enoxaparin or fondaparinux requires that patients be admin-
istered daily injections in an outpatient setting. This is often seen as an
inconvenience and could lead to reduced patient compliance and de-
creased efﬁcacy [8,9]. Edoxaban is the only new oral anticoagulant that
has been studied for the prevention of VTE in patients undergoing HFS.
Its ease of administration may offer an attractive thromboprophylactic
option for patients who cannot tolerate or comply with enoxaparin or
fondaparinux therapies.
This study does have somepotential limitations. It was a small study,
conducted only in 92 Japanese patients. The small study size does not
provide power for a statistical comparison between groups. This study
was in part designed to conﬁrm that the edoxaban dose of 30 mg once
daily, identiﬁed in phase 2b studies as the appropriate dose in
Japanese patients undergoing TKA or THA [12,13], was also appropriate
for patients undergoing HFS. As such, the sample size was set at 90 to
ensure that a major or CRNM bleeding event would occur in at least 1
patient with an 80% or higher probability in either treatment group.
Sixteen of 92 (17%) patients did not complete the study; the majority
of reasons for discontinuation were voluntary withdrawal and ineligi-
bility to continue in the study. However, 88 patients were included in
the safety analysis set to assess the primary endpoint of major, CRNM,
or minor bleeding.Conclusions
The results of this study show that a once-daily oral dose of
edoxaban 30 mg was comparable to sc enoxaparin 2000 IU BID with
regards to the safety/efﬁcacy balance for the prophylaxis of thrombo-
embolic events in patients who underwent HFS for medial or lateral
femoral neck fracture. This study, alongwith phase 3 studies in patients
undergoing TKA or THA, provided data that led to the approval in Japan
of once-daily, oral edoxaban 30mg for the prevention of VTE in patients
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